Stifel reduce el precio objetivo de las acciones de Nkarta a 11 dólares desde 12 dólares, mantiene calificación de Compra
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus